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Reply
We read with interest the comments on our study (1) by Drs.
Barbic and colleagues and Dr. Bonzi and colleagues.
Dr. Barbic and colleagues got the impression from our paper
that patients 25 to 44 years of age had twice the risk of death than
those older than 75 years of age. This misunderstanding is related
to the hazard ratios mentioned in our study in which the hazard
ratio in the 25 to 44 age group is 2.29, and that for those older than
75 years is 0.98. This is, of course, not the case, and the mentioned
hazard ratios are given for “syncope” compared with “controls” of
the same age group; thus, healthy individuals in the 25 to 44 age
group with syncope have twice the risk of the corresponding
control group without syncope. The relative relationship between
the age groups and the cumulative incidence of death can be seen
in Figure 1, where it is evident that with advanced age, the risk of
death is much higher.
Dr. Barbic and colleagues propose an intriguing hypothesis that
the increased mortality rate in these otherwise healthy patients
with syncope may be caused by work-related accidents. We share
their thoughts and are currently in the process of investigating the
impact of syncope on subsequent accidents, falls, and accidents
involving motor vehicles or large machinery compared with a
matched control population by linking the data provided in this
study with a database containing all data on accidents reported to
the Danish medical system. Hopefully these analyses will provide
data that could be useful for an evidence-based approach to
guidelines on the use of heavy machinery and motorized vehicles
after episodes of syncope.
Dr. Bonzi and colleagues whether our definition of low-risk
patients was appropriate and states that syncope most of the time
is the first manifestation of several diseases in healthy people. We
do not agree that this has been shown before in the referred
literature. We agree that the risk stratification developed is based
on many other factors than comorbidities, but the registries used
for our study do not include this information. Nevertheless, we
find that our study provides valid contemporary data and prognosis
on a very large population of “healthy” patients with syncope. We
also want to emphasize that our definition of healthy individuals
included that they were free of taking medications. Bonzi et al.
state that the results on 1-year mortality were inconclusive, but
we disagree with his interpretation because we clearly demonstrate
that in patients 25 to 74 years of age, “healthy or low-risk” people
with syncope have a significantly increased 1-year mortality rate
compared with matched controls. Finally, Bonzi et al. requests
the data re-analyzed on patients who were only seen in the
emergency department. Our study combined those discharged
from the emergency department with those discharged after
admission. We did, however, also look into those patients who
were discharged from the emergency department only, and the
results were consistent with the overall results. As you noted, there
was a typographical error in the online edition of the paper in theconfidence intervals of the age group younger than 25 years of age;
this was corrected in the print version.
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Reducing Hospitalizations for
Acute Decompensated Heart Failure
The Infusion Room Approach
Collins et al. (1) provide valuable insight into the complex
process and current dilemmas in managing patients who present
to the emergency department (ED) with acute heart failure
(HF). We would like to suggest an additional venue for the
management of this special population: the outpatient infusion
room (OIR), which is very similar to the observation unit
concept proposed by Collins et al. It too has the intended goal
to reduce hospital admissions and 30-day readmissions in a safe
and effective manner. At our institution, we have implemented
a Transitional Care Medicine program that works closely with
cardiologists in the outpatient setting in an effort to meet the
clinical and utilization management challenges that are associ-
ated with HF patients recently discharged from the hospital (2).
As one of the major components of the program, enrolled
patients are educated to contact the transitional care provider
via telephone at the earliest sign of decompensation (weight
gain, edema, shortness of breath, and/or increased fatigue).
Such early communication of symptoms leads to in-person evaluation
by the transitional care provider to help determine the optimal
disposition of the patient. Similar to Collins et al. (1) view-
point, we do not believe that all cases of decompensated HF
require hospital admission. Thus, we use the observation unit
for patients who require a moderate level of escalated care (i.e.,
24 h of intravenous [IV] diuretic therapy) because we recognize
the cost savings to the healthcare system by using this approach
(3). In even milder cases that still require more than traditional
outpatient care, we use the OIR in cases in which patients may
only need 12 h of IV diuretic therapy to relieve dyspnea, for
example. This decision is often guided by the familiarity that
the transitionalist has with the patient and past presentations of
that specific individual. Other institutions have used this
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mild to moderate acute HF and have demonstrated the safety
and efficacy of this clinical approach (4). We fully support the
evelopment of a systematic approach to determine the most
ppropriate disposition of patients with varying degrees of acute
ecompensated HF or risk profiles (home vs. observation unit
s. hospital admission). We believe that an OIR capability as
ell should be incorporated into such an approach. The costs
ssociated with treating patients with fluid overload due to
cute HF in this manner are considerably lower than traditional
pproaches without jeopardizing safety (2). We encourage
urther studies that can clearly assess how the use of both
bservation units and OIRs can affect the cost-effectiveness of
are in the HF population.
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Reply
We appreciate the interest in our viewpoint and the opportunity to
reply to the letter by Dr. Ota and colleagues concerning our paper (1)
and an outpatient infusion clinic as an alternative to hospitalization in
low-risk acute heart failure (AHF) patients. All alternatives to hospital
admission in patients with AHF need to be explored. As Dr. Ota and
colleagues suggest, patients’ level of disease severity may be one of the
determinants of where and for what duration they may be managed.
Our preliminary work suggests those patients presenting to the
emergency department with a low-risk clinical profile who require
symptomatic therapy could be managed in an observation unit, safely
avoiding inpatient admission. This strategy has been suggested to be
safe and efficacious in observational studies, but should be tested in a
prospective, randomized fashion beforewidespread implementation (2,3).
Lazkani and Ota (4) suggest the use of an outpatient infusion
clinic for those low-risk patients who may not need 24 to 48 h of
management. They report that this transitional strategy has been
successful when managing AHF patients recently discharged fromthe hospital (4). Patients engage in self-care and contact the
transitional care provider when they experience signs or symptoms
of worsening heart failure. However, this approach also requires
a formal study of safety and efficacy. This approach is similar to
outpatient infusions with inotropic agents or nesiritide. Al-
though these approaches appeared safe and efficacious in
preliminary studies, once studied in a prospective, randomized
manner, they were found to not improve outcomes (5,6). In the
absence of rigorously acquired data, we cannot support an
outpatient infusion clinic for heart failure. The observation unit
strategy that we propose is markedly different and is based on
the safe triage of low-risk patients with an emphasis on the use
of evidence-based therapy in a careful randomized manner that
should definitively address the utility of our approach.
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